secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-05-27T23:59:59+00:00
Accession:  0001193125-22-161235
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences publishes preclinical data on AU-011 + checkpoint inhibitors at ASCO 2022
--------------------------------------------------------------------------------

- AU-011 combined with immune checkpoint inhibitors showed efficacy against primary tumors and distant metastases in murine models.
- Data published as abstract e14544 in 2022 ASCO Annual Meeting proceedings (June 3-7, 2022).
- Collaboration with Leiden University Medical Center: survival data suggest potent targeted cytotoxicity on local tumors and metastases.
- Potential clinical application for choroidal melanoma and non-muscle invasive bladder cancer (NMIBC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522161235/0001193125-22-161235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312522161235/d348590d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-161235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer